focus -WSS

focus

author：comprehensive 2025-10-02 12:01:49 - browse：578

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Eli Lilly to pay $200M for Beam’s stake in gene

WSS

Senate panel to vote on hospitals, PBMs, prisoner care

Hospitals warn Medicare's drug payment fix is ‘unlawful’

WHO may add ‘noma' to its list of neglected tropical diseases

Printout prescription drug information shouldn’t go digital

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

How to save PrEP access — and even expand it

Biden's order seeks to regulate AI risk without stifling innovation

The high cost of giving birth even with insurance

FDA has safety concerns on CRISPR

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Guidelines to prevent youth baseball injuries need more muscle

TikTok, Instagram influencers need more rules for drug ads

How to save PrEP access — and even expand it

Medicare bonuses could stop drug shortages under Senate plan

hotspot

Maker of FluMist seeks to allow at

First Opinion Podcast: How to protect health care in times of war

Why Sanofi got shellacked over its spinoff

Diversifying clinical trials isn't enough to close racial gaps: study

Printout prescription drug information shouldn’t go digital

Biden's order seeks to regulate AI risk without stifling innovation

knowledge

hotspot

focus

Wikipedia